Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SLXNW
Upturn stock ratingUpturn stock rating

Biomotion Sciences Warrant (SLXNW)

Upturn stock ratingUpturn stock rating
$0.04
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/13/2025: SLXNW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -59.62%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/13/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.12
52 Weeks Range 0.01 - 0.18
Updated Date 06/5/2025
52 Weeks Range 0.01 - 0.18
Updated Date 06/5/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -193.54%
Return on Equity (TTM) -116.66%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 996278
Shares Outstanding -
Shares Floating 996278
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Biomotion Sciences Warrant

stock logo

Company Overview

overview logo History and Background

It is impossible to provide the history of Biomotion Sciences Warrant, including its founding year, significant milestones, and evolution over time, as the ticker is a warrant not a company and therefore will not have a company history.

business area logo Core Business Areas

leadership logo Leadership and Structure

It is impossible to outline Biomotion Sciences Warrant's leadership team and organizational structure as it is a warrant, not a company

Top Products and Market Share

overview logo Key Offerings

Market Dynamics

industry overview logo Industry Overview

Warrants are derivative securities that give the holder the right, but not the obligation, to purchase the underlying stock at a specified price (the exercise price) within a certain timeframe. Their value is derived from the underlying stock's performance and market volatility. The warrant market is tied to the overall stock market's health and investor sentiment.

Positioning

Biomotion Sciences Warrant's position is dependent on the underlying stock (if the underlying stock exist) performance and market sentiment towards that specific stock. It offers leveraged exposure to the underlying stock's price movements, both positive and negative. The warrant's potential upside is high if the underlying stock performs well, but the risk of total loss is also significant.

Total Addressable Market (TAM)

The TAM for warrants is difficult to quantify precisely, as it's a subset of the overall equity derivatives market. The TAM is influenced by factors like investor appetite for leverage, market volatility, and the number of companies offering warrants. Biomotion Sciences Warrant's potential within this TAM depends on the underlying stock's performance and its attractiveness to investors seeking leveraged exposure.

Upturn SWOT Analysis

Strengths

  • Leveraged exposure to the underlying stock
  • Potential for high returns with smaller initial investment
  • Can be used for hedging purposes

Weaknesses

  • High risk of total loss if the underlying stock doesn't perform well
  • Time decay as the expiration date approaches
  • Value is highly sensitive to the underlying stock's price volatility

Opportunities

  • Capitalize on potential growth of the underlying stock
  • Take advantage of market volatility to generate profits
  • Use warrants as part of a broader investment strategy

Threats

  • Decline in the underlying stock's price
  • Increase in market volatility can erode warrant value.
  • Expiration date approaching can cause rapid value decay

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

Since the ticker is a warrant, not a company, it does not have market share or competitors.

Growth Trajectory and Initiatives

Historical Growth: Warrant performance is tied to the underlying asset, and has no historical growth on it's own.

Future Projections: Future projections are entirely dependent on the trajectory of the underlying stock, and are difficult to assess with certainty.

Recent Initiatives: Since the ticker is a warrant, not a company, it will not have recent strategic initiatives.

Summary

Biomotion Sciences Warrant is a derivative security that provides leveraged exposure to its underlying stock. Its value is highly sensitive to the performance of the underlying asset and market volatility. The warrant offers high potential returns, but also carries a significant risk of total loss. Investors should carefully assess the underlying stock's prospects and their own risk tolerance before investing in this warrant.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • General market knowledge
  • Financial databases for stock and warrant information

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Warrants are complex financial instruments and carry a high degree of risk. Consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Biomotion Sciences Warrant

Exchange NASDAQ
Headquaters -
IPO Launch date 2024-08-16
Chairman & CEO Mr. Ilan Hadar M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 11
Full time employees 11

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.